MEMS  

 
  MEMS  
About MEMS   |   Council   |   Members Centre   |   Membership   |   Contact Us   |   Home
  Member Login     username:     password:           Forgot your password?
  Home » Announcements & Updates »  #OPMALINGSIAL » 
President’s Message
The Endocrine Directory
Calendar of Events
Announcements & Updates
#OPMALINGSIAL
Breaking News & Reports
CME
CPG
In the Press
Disease Areas
Healthy Lifestyle
Publications
Research Programs
Awards
Photo & Video Gallery
Useful Links
Disease Management
Home
 
arrow Assuring the safety of Novo Nordisk insulin analogues
29-07-2009
Why insulin analogues?
* Time-action profile of subcutaneous human insulin does not match physiological demand
* Human insulin preparations are not optimal for satisfying bolus and basal insulin requirements
»Read more...
 


arrow Novo Nordisk insulin analogues have proven safety profiles
29-07-2009
On Friday 26 June, Diabetologia, the journal of the European Association for the Study of Diabetes (EASD) published online data from four studies relating to a possible link between a long-acting insulin analogue, insulin glargine, and cancer1.
»Read more...
 


arrow Diabetes patients with high triglycerides and low HDL cholesterol get the most benefit from fenofibrate treatment: new data from the FIELD study
7-07-2009
Fenofibrate treatment reduces cardiovascular disease (CVD) risk (defined by total cardiovascular events: the composite of cardiovascular death, myocardial infarction, stroke, and coronary and carotid revascularization) in patients with type 2 diabetes and atherogenic dyslipidemia,
»Read more...
 


arrow Januvia and Janumet prescription
29-05-2009
As monotheraphyor in combination with other widely prescribed agents. Januvia decelivers substantial glucose reductions for a broad range of patients with type 2 diabetes

»Read more...
 


arrow JANUVIA® (sitagliptin) Dosage Information
28-05-2009
Indicated in patients with type 2 diabetes mellitus to improve glycemic control in combination with metformin as initial therapy or when the single agent alone, with diet and exercise does not provide adequate glycemic control. Initial combination therapy or maintenance of combination therapy may not be appropriate for all patients. These management options are left to the discretion of the health care provider.
»Read more...
 


arrow Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial
27-05-2009
Background Amputations in people with type 2 diabetes mellitus substantially impair their quality of life and impose high costs on health-care systems. Our aim was to assess the effect of fenofibrate on amputation events in a large cohort of patients with type 2 diabetes.
»Read more...
 


 
   
 



 
 
| | | |
© Copyright Malaysian Endocrine & Metabolic Society (MEMS)   2009 - 2016    All rights reserved.
designed & maintained: mobition